



**Supplemental Fig. 1** Graphical illustrations of creatinine at baseline and after each therapy according to CTCAE classification in 40 patients with both kidneys and with the same level of creatinine at baseline as with a single functioning kidney, for a comparison with the course of renal function. (A) at baseline, (B) after the first cycle (prior to the second cycle) of treatment, (C) after the second cycle (prior to the second cycle) of treatment, and (D) after the third cycle (prior to the fourth cycle) of  $^{177}\text{Lu-PSMA-617}$  RLT or at restaging. Renal function was already impaired at baseline in 27/40 (67.5%) patients, according to CTCAE G1 in 11/40 (27.5%) and G2 in 2/40 (5%). G1 and G2 renal functional impairment, respectively, were present in 9/40 (22.5%) and 2/40 (5.0%) of the patients after the first PRLT cycle and in 10/40 (25.0%) and 2/40 (5.0%) after the second cycle. No CTCAE grade 3 or 4 nephrotoxicity was observed during any of the treatment cycles and on a longer follow up.